微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 46.36% | -1.98% | 1.71% | 83/157 | 48.88% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 45.58% | -6.81% | 0.51% | 85/157 | 50.55% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 45.35% | -15.18% | -2.31% | 86/157 | 50.61% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 46.42% | -12.83% | -1.85% | 83/157 | -2.2% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 47.29% | -12.47% | -3.31% | 79/157 | 14.82% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 48.91% | -9.1% | -8.51% | 69/157 | 31.96% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 53.46% | -8.44% | 0.4% | 72/157 | 51.88% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 53.25% | -9.72% | -1.45% | 71/157 | 22.51% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 54.03% | -8.34% | 0.41% | 71/157 | 33.12% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 53.81% | -6.9% | -7.84% | 65/157 | 51.76% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 58.39% | 2.57% | -1.01% | 60/157 | 51.61% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 58.98% | -23.17% | 0.07% | 58/157 | 32.47% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 58.94% | -21.55% | 1.99% | 58/157 | 38.42% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 57.8% | -23.62% | 1.53% | 60/157 | 52.97% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 56.92% | -22.68% | -25.86% | 68/157 | 53.83% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 76.78% | 2.37% | 2.19% | 29/157 | 5.64% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 75.13% | -0.76% | -0.71% | 32/157 | 20.99% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 75.67% | 0.71% | 2.79% | 30/157 | 54.39% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 73.62% | -0.57% | -1.84% | 36/157 | 55.2% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 75% | 2.78% | -0.94% | 27/157 | 46.77% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 75.71% | 6.49% | 0.76% | 28/157 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 75.14% | 10.62% | 1.48% | 23/157 | 54.13% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 74.04% | 0.94% | 1.47% | 31/157 | -148.64% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 72.97% | -0.32% | 2.64% | 26/157 | 56.43% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 71.09% | -4.29% | 4.67% | 29/157 | 54.17% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 67.92% | -7.06% | -7.4% | 30/157 | 55.17% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 73.35% | -1.6% | 0.2% | 28/157 | -1242.15% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 73.2% | -0.91% | -1.46% | 21/157 | 55.23% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 74.28% | 1.3% | 1.65% | 22/157 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 73.08% | 0.64% | -1.97% | 19/157 | 51.07% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 74.55% | 5.63% | 0.9% | 27/157 | -211.97% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 73.88% | 13.17% | 0.75% | 17/157 | 54.14% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 73.33% | 22.25% | 0.98% | 17/157 | 53.53% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 72.62% | 24.28% | 2.9% | 17/157 | 54.16% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 70.57% | 20.33% | 8.11% | 26/157 | 52.55% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 65.28% | 10.65% | 8.83% | 23/157 | 49.09% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 59.99% | 2.4% | 2.66% | 29/157 | 47.91% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 58.43% | -3.42% | -0.37% | 25/157 | 46.94% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 58.65% | -7.19% | -0.59% | 33/157 | 48.46% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 59% | -7.39% | 0.72% | 22/157 | 46.19% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 58.58% | -8.12% | -3.18% | 26/157 | 46.26% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 60.5% | -4.17% | -4.26% | 20/157 | 43.86% | 贝达药业 | 97.01% | 行业排名> |